Novo A

Novo Nordisk is a premier global pharmaceutical company headquartered in Denmark, specializing in the treatment of diabetes, obesity, and other serious chronic conditions. Founded in 1923, the company has evolved from a regional insulin manufacturer into a world leader in cardiometabolic health, driven by its pioneering work in GLP-1 receptor agonists such as semaglutide (marketed as Ozempic and Wegovy). Novo Nordisk maintains a robust presence in rare blood and endocrine disorders while aggressively expanding its pipeline into cardiovascular disease, chronic kidney disease, and NASH. The company is characterized by its unique ownership structure under the Novo Nordisk Foundation and its commitment to innovative drug delivery, including oral biologics and next-generation injectable combinations.